242 related articles for article (PubMed ID: 11702096)
1. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.
Dekeyne A; Gobert A; Iob L; Cistarelli L; Melon C; Millan MJ
Psychopharmacology (Berl); 2001 Nov; 158(2):213-8. PubMed ID: 11702096
[TBL] [Abstract][Full Text] [Related]
2. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus.
Szabo ST; Blier P
Neuropsychopharmacology; 2001 Dec; 25(6):845-57. PubMed ID: 11750178
[TBL] [Abstract][Full Text] [Related]
3. Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors.
Gobert A; Billiras R; Cistarelli L; Millan MJ
J Neurosci Methods; 2004 Dec; 140(1-2):141-52. PubMed ID: 15589344
[TBL] [Abstract][Full Text] [Related]
4. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors.
Millan MJ; Dekeyne A
Int J Neuropsychopharmacol; 2007 Oct; 10(5):579-93. PubMed ID: 17076935
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action.
Page ME; Brown K; Lucki I
Psychopharmacology (Berl); 2003 Jan; 165(2):194-201. PubMed ID: 12426668
[TBL] [Abstract][Full Text] [Related]
6. Differential alpha-mediated inhibition of dopamine and noradrenaline release in the parietal and occipital cortex following noradrenaline transporter blockade.
Valentini V; Cacciapaglia F; Frau R; Di Chiara G
J Neurochem; 2006 Jul; 98(1):113-21. PubMed ID: 16805801
[TBL] [Abstract][Full Text] [Related]
7. Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors.
Dekeyne A; Gobert A; Auclair A; Girardon S; Millan MJ
Psychopharmacology (Berl); 2002 Jul; 162(2):156-67. PubMed ID: 12110993
[TBL] [Abstract][Full Text] [Related]
8. Discriminative stimulus properties of cocaine: enhancement by monoamine reuptake blockers.
Kleven MS; Koek W
J Pharmacol Exp Ther; 1998 Mar; 284(3):1015-25. PubMed ID: 9495862
[TBL] [Abstract][Full Text] [Related]
9. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex.
Page ME; Lucki I
Neuropsychopharmacology; 2002 Aug; 27(2):237-47. PubMed ID: 12093597
[TBL] [Abstract][Full Text] [Related]
10. Does combined treatment with novel antidepressants and a dopamine D3 receptor agonist reproduce cocaine discrimination in rats?
Filip M; Papla I
Pol J Pharmacol; 2001; 53(6):577-85. PubMed ID: 11985331
[TBL] [Abstract][Full Text] [Related]
11. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex.
Kihara T; Ikeda M
J Pharmacol Exp Ther; 1995 Jan; 272(1):177-83. PubMed ID: 7815331
[TBL] [Abstract][Full Text] [Related]
12. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
Millan MJ; Dekeyne A; Papp M; La Rochelle CD; MacSweeny C; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2001 Aug; 298(2):581-91. PubMed ID: 11454919
[TBL] [Abstract][Full Text] [Related]
13. The reboxetine-induced increase of accumbal dopamine efflux is inhibited by l-propranolol: a microdialysis study with freely moving rats.
Mizoguchi N; Saigusa T; Aono Y; Sekino R; Takada K; Oi Y; Ueda K; Koshikawa N; Cools AR
Eur J Pharmacol; 2008 Dec; 601(1-3):94-8. PubMed ID: 18996113
[TBL] [Abstract][Full Text] [Related]
14. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
Millan MJ; Gobert A; Lejeune F; Newman-Tancredi A; Rivet JM; Auclair A; Peglion JL
J Pharmacol Exp Ther; 2001 Aug; 298(2):565-80. PubMed ID: 11454918
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus properties of antidepressant agents: a review.
Dekeyne A; Millan MJ
Behav Pharmacol; 2003 Sep; 14(5-6):391-407. PubMed ID: 14501253
[TBL] [Abstract][Full Text] [Related]
16. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test.
O'Leary OF; Bechtholt AJ; Crowley JJ; Hill TE; Page ME; Lucki I
Psychopharmacology (Berl); 2007 Jun; 192(3):357-71. PubMed ID: 17318507
[TBL] [Abstract][Full Text] [Related]
17. Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine.
Fossa AA; Wisialowski TA; Cremers T; van der Hart M; Tseng E; Deng S; Rollema H; Wang EQ
Toxicol Appl Pharmacol; 2012 Nov; 264(3):343-50. PubMed ID: 23000177
[TBL] [Abstract][Full Text] [Related]
18. Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies.
Masana M; Castañé A; Santana N; Bortolozzi A; Artigas F
Neuropharmacology; 2012 Sep; 63(4):675-84. PubMed ID: 22652058
[TBL] [Abstract][Full Text] [Related]
19. Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data.
Agelink MW; Ullrich H; Baumann B; Strum S; Majewski T
Psychopharmacology (Berl); 2002 Sep; 163(2):151-6. PubMed ID: 12202961
[TBL] [Abstract][Full Text] [Related]
20. Effect of co-administration of lithium and reboxetine on extracellular monoamine concentrations in rats.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2004 Apr; 489(3):187-91. PubMed ID: 15087241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
